The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market ...

The Phase II segment is a randomised, double-blind, placebo-controlled study assessing ABCL635 efficacy in 80 postmenopausal ...

Early-phase clinical trials, those first-in-human studies, are where years of research and millions in investment meet the ...

Companies across the globe are diligently working toward developing novel Dry Age Macular Degeneration treatment therapies ...

FDA Clears IND Allowing Phase 2a Trial of NAV-240 in Hidradenitis Suppurativa to Begin Dosing in Q1 2026HREC Approval ...

– Company Expects to Initiate Phase 2b Study in Mid-2024 – CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism ...

In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...

Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program ...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Thursday announced that the FDA has granted the company's request for an End of Phase 2 meeting to discuss its proposed clinical development plan and seek ...

Many clinical trials include a placebo group—participants who receive an inactive treatment—so researchers can compare ...